A recent publication in Epilepsia described some aspects of the interaction between cannabidiol and clobazam, an antiepileptic drug, using preclinical models. The researchers claim “we provide unprecedented evidence that CBD potently inhibits the metabolism of clobazam… and, to a lesser extent [its metabolite, N-desmethylclobazam].” While their study provides some useful new insight, they’re about five years late to the game. The precedent was set in a much more relevant clinical report from June 2015. Since then, report after report has described these interactions, in scientific journals and more accessible reporting (we hope). Replication is essential in research - there is no need for exaggeration.